Cullinan's lung cancer drug has a February PDUFA date for second-line indication following positive first-line phase three data.
“The PDUFA date is in February. They've now got a first line, study that just read out this week, that was also positive.”
→ Read the source episode
Our resolution criterion
disputableFDA issues approval or rejection decision on Cullinan's lung cancer drug by February PDUFA date
More from Biotech Hangout
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.